Experimental group: anlotinib(d1-14, d22-36), followed by 21 days period, 2 weeks medication, 1 week maintenance therapy.
. Group II: 10 mg po qd, Group III: 12 mg po qd;
Combined chemotherapy:
Cisplatin + etoposide Or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + cultured beauty (non squamous cell carcinoma). Synchrotron radiation: radiotherapy combined with radiotherapy (3D-CRT or IMRT) (60-66Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

Patients With Non-small Cell Lung Cancer

Simultaneous chemoradiotherapy for An Luo

The second affiliated Hospital of Xi'an Jiaotong University

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Phase I / II Clinical Study on the Safety and Preliminary Efficacy of Anlotinib Hydrochloride Combined With Platinum-containing Simultaneous Radiotherapy in the Treatment of Locally Advanced Non-small Cell Lung Cancer

complete response(CR)+partial response(PR) according to RECIST 1.1

overall survival is defined as the time from randomization to death from any cause

progression-free survival is defined as the time from enrollment to the date of first document disease progression or death from any cause

Second Affiliated Hospital of Xi'an Jiaotong University

Tang-Du Hospital

Xijing Hospital

First Affiliated Hospital Xi'an Jiaotong University

Shaanxi Provincial Cancer Hospital

Shaanxi Provincial People's Hospital

Experimental group: anlotinib (D1-14, d22-36, followed by 21 days cycle, taking medicine for 2 weeks, stopping for 1 week).
Group 1: 8mg po qd, Group 2: 10mg po qd, Group 3: 12mg po qd;
Combined chemotherapy:
Cisplatin + etoposide or PC: carboplatin AUC2, paclitaxel 45-50 mg 2 per week; Cisplatin + pemetrexed (non-squamous cell carcinoma). Simultaneous radiotherapy: 3D-CRT or IMRT external radiotherapy (60-66 Gy, 2.0 Gy / day).
The curative effect was evaluated after 6 weeks of simultaneous radiotherapy and chemotherapy combined with alotinib, and then the efficacy of alotinib or chemotherapy was maintained until PD.

Migalastat administered according to SmPC

Fabry Disease

Universtiy Hospital Münster

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

Primary endpoint of the observational study is the change in left ventricular mass index (LVMI) over two years.

Incidence of transient/manifest cerebral ischemia or stroke over 24 months.

Change in severity of neuropathic pain measured by Graded Chronic Pain Scale (GCPS)

Change in severity of neuropathic pain measured by Neuropathic Pain Symptom Inventory (NPSI) Score (items are quantified on a (0-10) numerical scale).

Change in disease severity measured by Mainz Severity Score Index (MSSI)

Change in disease severity measured by the Disease Severity Scoring System (DS3)

Change of White Matter Lesion load (quantified by WML volumetry [ml]).

Stabilization of cerebral microbleeds/hemorrhagic lesions.

Change in gastrointestinal symptoms (gastrointestinal symptoms rating scale, GSRS).

Change in quality of life (Short Form (SF-36) Health Survey: 36-item, patient-reported survey of patient health).

cerebral infarction/hnačka

Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.

Najkompletnejšia databáza liečivých bylín podporovaná vedou